AGAVE-201: Axatilimab for cGVHD

EP: 1.Differentiating Acute and Chronic Graft-vs-Host Disease

EP: 2.Navigating Chronic GVHD: Phases of Pathophysiology and Best Practices in Patient Monitoring

EP: 3.Optimizing Chronic GVHD Therapy

EP: 4.Navigating Treatment Decisions in Chronic GVHD

EP: 5.Overview of Advanced Therapies in cGVHD

EP: 6.Overview of the ROCKstar Study

EP: 7.Considerations for Third-Line Treatment in Chronic GVHD

EP: 8.Clinical Scenario: Treatment Selection in the third line and beyond in cGVHD

EP: 9.Recent Updates: REACH3, ROCKstar, and RWD

Now Viewing

EP: 10.AGAVE-201: Axatilimab for cGVHD

EP: 11.Emerging Trends in Chronic GVHD: Promising Clinical Trials and the Future Treatment Landscape

EP: 12.Clinical Impact of Patient-Reported Outcomes in cGVHD

EP: 13.Multidisciplinary Approaches to GVHD

Video content above is prompted by the following:

• Axatilimab is pending FDA approval for cGVHD after failure of at least 2 prior lines of systemic therapy. Discuss its mechanism of action (MOA) and how this MOA might add value to cGVHD treatment landscape.
• Discuss phase 1/2 data (Kitko CL, et al. J Clin Oncol. 2022) and AGAVE-201 trial data with axatilimab for cGVHD (Wolff D, et al. ASH 2023).